Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06117891 · ClinicalTrials.gov registry record

An Observational Study to Learn More About How Well a Treatment Works When Given After Treatment With Atezolizumab and Bevacizumab or Another Similar Combination of Drugs in Adults With Liver Cancer That Cannot be Treated With Surgery

A clinical trial of Unresectable Hepatocellular Carcinoma, sponsored by Bayer.

Recruiting
Registry status
300
Enrollment target
20
Study locations

NCT06117891 is a study of Unresectable Hepatocellular Carcinoma that is actively recruiting participants, run by Bayer. The registered enrollment target is 300 participants, above the 62-participant average among 12 other Unresectable Hepatocellular Carcinoma trials with a reported enrollment target (384% higher). The trial reports 20 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06117891, a study of Unresectable Hepatocellular Carcinoma, is actively recruiting participants, sponsored by Bayer.

RECRUITING
Registry status
300 participants
Enrollment target
20
Study locations

Study Summary

This is an observational study in which only data will be collected from adults with unresectable hepatocellular carcinoma. These adults should be prescribed a different treatment after treatment with atezolizumab and bevacizumab, or another similar combination of drugs, by their doctors. Unresectable hepatocellular carcinoma (uHCC) is a type of liver cancer that cannot be treated with surgery. In the past, sorafenib was the only approved first-line anti-cancer drug for people with uHCC. Regorafenib and other drugs were approved as second-line treatments for uHCC if a person could not take sorafenib or it stopped working for them. Lately, another first-line (1L) treatment called immuno-oncology (IO) immune checkpoint inhibitor combination (1L-IO combo), like atezolizumab with bevacizumab (AB), has become the preferred choice of treatment. This is because of the meaningful impact on patient survival. 1L-IO combo are drugs that help the body's defense system recognize and kill cancer cells. Since the other treatments were previously approved for use following sorafenib, the best order to take these treatments in following an 1L-IO combo is unknown. To better understand and determine this order, more knowledge is needed about how well different treatments work in participants with uHCC who have been treated with AB or another 1L-IO combo. The main purpose of this study is to learn more about how well different treatments work when given after first-line treatment with AB or another approved 1L-IO combo. To do this, researchers will collect data on how long the participants live (also called overall survival) from the start of any treatment given after the first-line treatment. In addition, researchers will also collect the following information to learn more about the participants who will be given a different treatment after the 1L-IO combo: * characteristics including age, sex, and race, and signs and symptoms of the participants over the duration of their fi

Conditions Studied

Unresectable Hepatocellular Carcinoma

Interventions

  • DRUG Bevacizumab
  • DRUG Atezolizumab
  • DRUG Durvalumab
  • DRUG Tremelimumab,

Study Locations (20)

Other

  • Many Locations - Multiple Locations
  • Many Locations - Multiple Locations
  • Many Locations - Multiple Locations
  • Many Locations - Multiple Locations
  • Many Locations - Multiple Locations
  • Many Locations - Multiple Locations
  • Many Locations - Multiple Locations
  • Many Locations - Multiple Locations
  • Many Locations - Multiple Locations
  • Many Locations - Multiple Locations
  • Many Locations - Multiple Locations
  • Many Locations - Multiple Locations
  • Many Locations - Multiple Locations
  • Many Locations - Multiple Locations

Pennsylvania

  • Corporal Michael J Crescenz Department Of Veterans Affairs Medical Center - Philadelphia
  • Einstein Medical Center - Philadelphia

Maryland

  • Mercy Medical Center - Medline Healthcare Services LLC - Baltimore

Michigan

  • University of Michigan Health System - Ann Arbor

New York

  • Roswell Park Comprehensive Cancer Center - Buffalo

Ohio

  • University Of Cincinnati Division Of Hematology Oncology - UC Health System - Cincinnati

Trial Details

FieldValue
Enrollment Target 300 participants
Start Date 2023-11-27
Est. Completion 2027-02-01

Sponsor

Bayer

591 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06117891

The ClinicalTrials.gov registry entry for NCT06117891 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 62-participant average among 12 other Unresectable Hepatocellular Carcinoma trials with a reported enrollment target (384% higher). The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Unresectable Hepatocellular Carcinoma appearing as the primary indexed condition, and to 4 interventions - of which Bevacizumab is the first listed.

NCT06117891 reports 20 study locations spanning 6 distinct geographic areas - top geographies include Other, Pennsylvania, Maryland.

Frequently Asked Questions

What is clinical trial NCT06117891 about?

NCT06117891 is a clinical study titled "An Observational Study to Learn More About How Well a Treatment Works When Given After Treatment With Atezolizumab and Bevacizumab or Another Similar Combination of Drugs in Adults With Liver Cancer That Cannot be Treated With Surgery". This is an observational study in which only data will be collected from adults with unresectable hepatocellular carcinoma. These adults should be prescribed a different treatment after treatment with atezolizumab and bevacizumab, or another similar combination of drugs, by their doctors. Unresecta...

What is the current status of trial NCT06117891?

This trial is currently recruiting. The enrollment target is 300 participants. The study started on 2023-11-27. Estimated completion is 2027-02-01.

What conditions does trial NCT06117891 study?

This clinical trial studies the following conditions: Unresectable Hepatocellular Carcinoma.

What interventions are being tested in trial NCT06117891?

The interventions under investigation include: Bevacizumab (DRUG), Atezolizumab (DRUG), Durvalumab (DRUG), Tremelimumab, (DRUG).

Who is sponsoring clinical trial NCT06117891?

This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06117891 being conducted?

This trial has 20 study locations across Maryland, Michigan, New York, Ohio, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Unresectable Hepatocellular Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Unresectable Hepatocellular Carcinoma

All registered trials for this condition

Maryland

All trials with a study site in Maryland

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.